BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34975010)

  • 21. [CD7 expression and its prognostic significance in acute myeloid leukemia patients with wild-type or mutant CEBPA].
    Zhu MY; Zhu Y; Chen RR; Zhu LX; Zhu JJ; Li XY; Zhou D; Yang XD; Zheng YL; Xie MX; Sun JN; Huang XB; Li L; Xie WZ; Ye XJ
    Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):100-105. PubMed ID: 32135624
    [No Abstract]   [Full Text] [Related]  

  • 22. Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome.
    Iriyama N; Asou N; Miyazaki Y; Yamaguchi S; Sato S; Sakura T; Maeda T; Handa H; Takahashi M; Ohtake S; Hatta Y; Sakamaki H; Honda S; Taki T; Taniwaki M; Miyawaki S; Ohnishi K; Kobayashi Y; Naoe T
    Ann Hematol; 2014 Jun; 93(6):957-63. PubMed ID: 24441947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
    El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
    Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence and impact of colony stimulating factor 3 receptor (CSF3R) mutations among Egyptian acute myeloid leukemia patients.
    Aref S; El-Ghonemy M; Abouzeid T; El-Sabbagh A; El-Baiomy M
    Leuk Res; 2014 Jun; 38(6):722-5. PubMed ID: 24746896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [CEBPA gene mutation analysis in acute myeloid leukemia].
    Han C; Lin D; Ai XF; Wang F; Sun HY; Wang M; Mi YC; Wang JX; Ru K
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):566-71. PubMed ID: 23906447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia.
    Braun TP; Okhovat M; Coblentz C; Carratt SA; Foley A; Schonrock Z; Curtiss BM; Nevonen K; Davis B; Garcia B; LaTocha D; Weeder BR; Grzadkowski MR; Estabrook JC; Manning HG; Watanabe-Smith K; Jeng S; Smith JL; Leonti AR; Ries RE; McWeeney S; Di Genua C; Drissen R; Nerlov C; Meshinchi S; Carbone L; Druker BJ; Maxson JE
    Nat Commun; 2019 Nov; 10(1):5455. PubMed ID: 31784538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors.
    Lavallée VP; Krosl J; Lemieux S; Boucher G; Gendron P; Pabst C; Boivin I; Marinier A; Guidos CJ; Meloche S; Hébert J; Sauvageau G
    Blood; 2016 Jun; 127(24):3054-61. PubMed ID: 27034432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML.
    Maxson JE; Ries RE; Wang YC; Gerbing RB; Kolb EA; Thompson SL; Guidry Auvil JM; Marra MA; Ma Y; Zong Z; Mungall AJ; Moore R; Long W; Gesuwan P; Davidsen TM; Hermida LC; Hughes SB; Farrar JE; Radich JP; Smith MA; Gerhard DS; Gamis AS; Alonzo TA; Meshinchi S
    Blood; 2016 Jun; 127(24):3094-8. PubMed ID: 27143256
    [No Abstract]   [Full Text] [Related]  

  • 29. Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
    Matsuo H; Kajihara M; Tomizawa D; Watanabe T; Saito AM; Fujimoto J; Horibe K; Kodama K; Tokumasu M; Itoh H; Nakayama H; Kinoshita A; Taga T; Tawa A; Taki T; Tanaka S; Adachi S
    Blood Cancer J; 2014 Jul; 4(7):e226. PubMed ID: 25014773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia.
    Wakita S; Sakaguchi M; Oh I; Kako S; Toya T; Najima Y; Doki N; Kanda J; Kuroda J; Mori S; Satake A; Usuki K; Ueki T; Uoshima N; Kobayashi Y; Kawata E; Tajika K; Nagao Y; Shono K; Shibusawa M; Tadokoro J; Kayamori K; Hagihara M; Uchiyama H; Uchida N; Kubota Y; Kimura S; Nagoshi H; Ichinohe T; Kurosawa S; Motomura S; Hashimoto A; Muto H; Sato E; Ogata M; Mitsuhashi K; Ando J; Marumo A; Omori I; Fujiwara Y; Terada K; Yui S; Arai K; Kitano T; Miyata M; Kurosawa A; Mizoguchi A; Komatsu N; Fukuda T; Ohashi K; Kanda Y; Inokuchi K; Yamaguchi H
    Blood Adv; 2022 Jan; 6(1):238-247. PubMed ID: 34448807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia.
    Ahn SY; Kim T; Kim M; Song GY; Jung SH; Yang DH; Lee JJ; Kim MY; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim HJ; Ahn JS; Kim DDH
    Cancer Res Treat; 2023 Jul; 55(3):1011-1022. PubMed ID: 36701843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis.
    Li HY; Deng DH; Huang Y; Ye FH; Huang LL; Xiao Q; Zhang B; Ye BB; Lai YR; Mo ZN; Liu ZF
    Eur J Haematol; 2015 May; 94(5):439-48. PubMed ID: 25227715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Companion gene mutations and their clinical significance in AML with double or single mutant CEBPA.
    He J; Liu J; Shen H; Wang Z; Cao L; Wu P; Chao H; Lu X; Jia Z; Chen M; Cai X
    Int J Hematol; 2022 Jul; 116(1):71-80. PubMed ID: 35314954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.
    Hou HA; Lin YC; Kuo YY; Chou WC; Lin CC; Liu CY; Chen CY; Lin LI; Tseng MH; Huang CF; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
    Ann Hematol; 2015 Feb; 94(2):211-21. PubMed ID: 25241285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Laboratory evaluation and prognostication among adults and children with CEBPA-mutant acute myeloid leukemia.
    Mendoza H; Podoltsev NA; Siddon AJ
    Int J Lab Hematol; 2021 Jul; 43 Suppl 1():86-95. PubMed ID: 34288448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of CSF3R mutations in atypical chronic myeloid leukemia and other myeloid malignancies.
    Kim SY; Song IC; Kim J; Kwon GC
    Ann Diagn Pathol; 2024 Aug; 71():152317. PubMed ID: 38642470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutational spectrum of acute myeloid leukemia patients with double
    Su L; Tan Y; Lin H; Liu X; Yu L; Yang Y; Liu S; Bai O; Yang Y; Jin F; Sun J; Liu C; Liu Q; Gao S; Li W
    Oncotarget; 2018 May; 9(38):24970-24979. PubMed ID: 29861846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Familial CEBPA-mutated acute myeloid leukemia.
    Tawana K; Rio-Machin A; Preudhomme C; Fitzgibbon J
    Semin Hematol; 2017 Apr; 54(2):87-93. PubMed ID: 28637622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia.
    Marcolin R; Guolo F; Minetto P; Clavio M; Manconi L; Ballerini F; Carli A; Passannante M; Colombo N; Carminati E; Pugliese G; Tedone E; Contini P; Mangerini R; Kunkl A; Miglino M; Cagnetta A; Cea M; Gobbi M; Lemoli RM
    Leuk Res; 2019 Nov; 86():106223. PubMed ID: 31557597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.